Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence

Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence

The recombinant zoster vaccine (RZV) was licensed in the US for prevention of herpes zoster (HZ) in 2017. We conducted a literature search (January 1, 2017–August 1, 2023) using PubMed, Embase, and Scopus to consolidate the real-world evidence related to RZV. Overall, RZV effectiveness against HZ wa...

Full description

Saved in:
Bibliographic Details
Main Authors: Raunak Parikh, David Singer, Elizabeth Chmielewski-Yee, Christophe Dessart
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Autoimmune disease
completion rate
effectiveness
herpes zoster
immunodeficiency
immunosuppression
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2023.2263979
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2023.2263979

Similar Items